Thalassemia

No link between deferiprone and liver fibrosis in transfused patients

Published in Hepatitis Weekly, September 30th, 2002

by Sonia Nichols, senior medical writer - The results of an international multicenter study suggest the chelation drug deferiprone does not contribute to hepatic fibrosis in people who receive blood transfusions for thalassemia.

Deferiprone is used for ensuring thalessemia patients do not develop iron-induced organ damage as a result of the numerous iron transfusions they must receive. There have been conflicting reports concerning the role deferiprone plays in worsening fibrosis progression, according to Ian R. Wanless, an investigator in the Department of Laboratory and Pathobiology at the University of Toronto in Ontario, Canada. In one of the largest studies of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry